Premium
Antimalarial Therapy for Lupus Erythematosus: An Apparent Advantage of Quinacrine
Author(s) -
Zuehlke Richard L.,
Lillis Patrick J.,
Tice Ann
Publication year - 1981
Publication title -
international journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 93
eISSN - 1365-4632
pISSN - 0011-9059
DOI - 10.1111/j.1365-4362.1981.tb05295.x
Subject(s) - medicine , chloroquine , lupus erythematosus , dermatology , drug , systemic lupus erythematosus , side effect (computer science) , aplastic anemia , immunology , pharmacology , malaria , disease , antibody , bone marrow , computer science , programming language
A retrospective study of 26 quinacrine‐treated lupus erythematosus patients failed to show evidence of drug‐induced ocular changes. Although quinacrine commonly produces minor side effects, such as yellow discoloration of the skin, and may rarely produce very serious side effects, such as aplastic anemia, it appears to produce much less oculotoxicity than does chloroquine.